Glitazone (thiazolidinediones);Les glitazones (thiazolidinediones)

Revue Medicale de Bruxelles

Volumn 21, Issue 5, 2000, Pages 441-446

  Ducobu, J ^a   Sternon, J ^b  

^a Centre Hospitalier Universitaire de Tivoli   (Belgium)

^b CHU Tivoli ^*

Author keywords

Diabetes 2; Insulin resistance; Peroxisome Proliferator Activated Receptors; Thiazolidinediones; Troglitazone

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BIGUANIDE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TROGLITAZONE;

CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COLON POLYP; DRUG EFFICACY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SAFETY; FLUID RETENTION; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TREATMENT; LIPID OXIDATION; LIVER DYSFUNCTION; LIVER FAILURE; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; DIABETES MELLITUS, TYPE 2; GLUCONEOGENESIS; HEPATITIS, TOXIC; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; RATS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THIAZOLES; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS;

EID: 0033743895     PISSN: 00353639     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Cariou B, Charbonnel B : Nouveautés dans le traitement du diabète de type 2. Actualités diabétologiques de l'Hôtel Dieu. Médecine Science Flammarion, Paris, 1999
2. Saltiel AR, Olefsky JM : Thiazolidinediones in the treatment of insulin resistance and type 2 diabetes. Diabetes 1996 ; 45 : 1661-9
3. Iwamoto Y, Kosaka K, Kuzuga T et al : Effects of troglitazone. A new hypoglycaemic agent in patients with NIDDM poorly controlled by diet therapy. Diabetes Care 1996 ; 19 : 151-6
4. Plosker GL, Faulds D : Troglitazone : a review of its use in the management of type 2 diabetes mellitus. Drugs 1999 ; 57 : 409-38
5. Day C : Thiazolidinediones: a new class of antidiabetic drugs. Diabet Med 1999 ; 16 : 179-92
6. Berger J, Bailey P, Biswas C et al : Thiazolidinediones produce a conformational change in peroxisomal proliferator activated receptor-γ : binding and activation correlate with antidabetic actions in db/DB mice. Endocrinology 1996 ; 137 : 4189-95
7. Desvergne B, Wahli W : Peroxisome Proliferator Activity Receptors : nuclear control of metabolism. Endocrinol Rev 1999 ; 20 : 649-88
8. Auwers J : PPARγ, the ultimate thrifty gene. Diabetologia 1999 ; 42 : 1033-49
9. Martin G, Schoonjans K, Lefevre A, Staels B, Auwers J : Coordinate regulation of the expression of the fatty acid transport protein (FATP) and acyl CoA synthetase genes by PPARα activators. J Biol Chem 1997 ; 272 : 28210-7
10. Schoonjans K, Auwerx J : Thiazolidinediones : an update. Lancet 2000 ; 355 : 1008-10
11. Fajas L, Fruchart JC, Auwerx J : Transcriptional control of adipogenesis. Curr Opin Cell Biol 1998 ; 10 : 165-73
12. Dark K, Abrams L, Nikoulina S et al : Effect of troglitazone on glucose transport, glycogen synthase activity in human skeletal muscle cultures from obeses non-diabetic and NIDDM subjects. Diabetes 1996 ; 45 (suppl 2) : A93
13. Tafuri SR : Troglitazone enhances basal glucose uptake and GLUT protein levels in 3T3-L1 adipocytes. Endocrinol 1996 ; 137 : 4706-12
14. Fulgencio JP, Kohl C, Girard J et al : Troglitazone inhibits fatty acid oxidation and esterification, and gluconeogenesis in isolated hepatocytes from starved rats. Diabetes 1996 ; 45 : 1536-42
15. Nolan JJ, Ludvik B, Beerdsten P et al : Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 1994 ; 331 : 1188-93
16. Inzucchi SE, Maggs DG, Spollett GR et al : Efficacy and metabolic effects of metformin and troglitazone in type 11 diabetes. N Engl J Med 1998 ; 338 : 867-72
17. Cominanici L, Garbin U, Pasini AF et al : Troglitazone reduces LDL oxidation and lowers plasma E-selectin concentration in NIDDM patients. Diabetes 1998 ; 47 : 130-3
18. Minakawa J, Tanaka S, Yamanchi M et al : Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 1998 ; 83 : 1818-20
19. Spencer CM, Markham A : Troglitazone. Drugs 1997 ; 54 : 89-102
20. Scheen AJ, Lefebvre PJ : Troglitazone : antihyperglycemic activity and potential role in the treatment of type 2 diabetes. Diabetes Care 1999 ; 22 : 1568-77
21. Sunayama S, Watanabe Y, Daida H, Yamaguchi H : Thiazolidinediones, dyslipidemia and insulin resistance syndrome. Curr Opin Lipidol 2000 ; 11 : 397-402
22. Schwartz S, Raskin P, Fonseac VA et al : Effects of troglitazone in insulin-treated patients with type 2 diabetes mellitus. N Engl J Med 1998 ; 338 : 361-6
23. Fonseca VA, Valiquet TR, Huang SM et al : Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus : a randomized, controlled study. J Clin Endocrinol Metab 1998 ; 83 : 3169-76
24. Krenz AJ, Bailey CJ, Melawder A : Thiazolidinediones for type 2 diabetes. BMJ 2000 ; 321 : 252-3
25. Watkins PB, Whitcomb RW : Hepatic dysfunction associated with troglitazone. N Engl J Med 1998 ; 338 : 916-7
26. Neuschwander-Tetri BA, Isley WL, Ohi JC et al : Troglitazone-induced hepatic failure leading to liver transplantation. Ann Intern Med 1998 ; 129 : 38-41
27. Bailey CJ : Rosiglitazone and pioglitazone: two new thiazolidinediones. Pratical Diabetes Int 2000 ; 17 : 1-3
28. Freid J, Everitt D, Boscla J : Rosiglitazone and hepatic failure. Ann Intern Med 2000 ; 132 : 164
29. Saey E, Tontenoz P, Nelson MC et al : Activators of the nuclear receptor PPARγ enhance colon polyp formation. Nature Med 1998 ; 4 : 1058-61
30. Bailey CJ : The rise and fall of troglitazone. Diabet Med 2000 ; 17 : 414